The NICE ADHD health technology assessment: A review and critique

Child and Adolescent Psychiatry and Mental Health

Volumn 2, Issue , 2008, Pages

  Schlander, Michael ^a,b,c  

^a Institute for Innovation and Valuation in Health Care (InnoValHC)   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Fachhochschule Ludwigshafen   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ATOMOXETINE; DEXAMPHETAMINE; EQUASYM XL; LONG ACTING DRUG; METHYLPHENIDATE; SHORT ACTING DRUG;

ADOLESCENT DISEASE; ATTENTION DEFICIT DISORDER; BIOMEDICAL TECHNOLOGY ASSESSMENT; CAREGIVER BURDEN; CHILDHOOD DISEASE; CLINICAL EFFECTIVENESS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; ECONOMIC EVALUATION; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH SERVICE; HUMAN; MEDICAL SOCIETY; PRIORITY JOURNAL; QUALITY OF LIFE; REVIEW; UNSPECIFIED SIDE EFFECT;

EID: 45149098455     PISSN: None     EISSN: 17532000     Source Type: Journal    
DOI: 10.1186/1753-2000-2-1     Document Type: Review

References (68)

1. Gilbody SM Petticrew M Rational decision-making in mental health: The role of systematic reviews Journal of Mental Health Policy and Economics 1999, 2:99-106 10.1002/ (SICI)1099-176X(199909)2:3<99::AID-MHP51>3.0.CO;2-C
2. World Health Organization (WHO) Technology appraisal programme of the National Institute for Clinical Excellence. A review by WHO. June-July 2003 Copenhagen: World Health Organization (WHO) 2003 http://www.nice.org.uk/Docref.asp?d=85797
3. National Institute for Health and Clinical Excellenc (NICE) Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents. Review of Technology Appraisal 13 London: NICE, March 2006
4. King S Griffin S Hodges Z Weatherly H Asseburg C Richardson G Golder S Taylor E Drummond M Riemsma R A systematic review of the clinical and cost-effectiveness of methylphenidate hydrochloride, dexamfetamine sulphate and atomoxetine for attention deficit hyperactivity disorder (ADHD) in children and adolescents (commercial in confidence information removed) York 2004
5. Pearson SD Rawlins MD Quality, innovation, and value for money. NICE and the British National Health Service Journal of the American Medical Association (JAMA) 2005, 294:2618-2622 10.1001/jama.294.20.2618
6. Centers for Disease Control and Prevention (CDC) Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder - United States, 2003 MMWR Morbidity and Mortality Weekly Report 2005, 54:842-847
7. National Institute for Clinical Excellence (NICE) Guide to the Technology Appraisal Process (reference N0514) London: NICE 2004
8. National Institute for rClinical Excellence (NICE) Guide to the Methods of Technology Appraisal (reference N0515) London: NICE 2004
9. Daniels N Sabin JE Setting Limits Fairly - Can We Learn to Share Medical Resources? Oxford, Oxford University Press 2002
10. Schlander M NICE accountability for reasonableness. A qualitative case study of its appraisal of treatments for attention-deficit/hyperactivity disorder (ADHD) Current Medical Research & Opinion 2007, 23:207-222 10.1185/030079906X159461
11. Schlander M Health Technology Assessments by the National Institute for Health and Clinical Excellence (NICE): A case study of its recent appraisal of treatment strategies for attention-deficit/hyperactivity disorder New York, NY, Springer 2007
12. King S Griffin S Hodges Z Weatherly H Asseburg C Richardson G Golder S Taylor E Drummond M Riemsma R A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents Health Technology Assessment 2006, 10:23 16796929
13. National Institute for Clinical Excellence (NICE) Health Technology Appraisal: Methylphenidate, atomoxetine and dexamfetamine for attention deficit hyperactivity disorder (ADHD) in children and adolescents including review of existing guidance number 13 (Guidance on the Use of Methylphenidate [Ritalin, Equasym] for Attention Deficit/Hyperactivity Disorder [ADHD] in childhood) - Scope London: NICE 2003
14. King S Riemsma R Hodges Z Emmany Dean M Golder S Drummond M Weatherly H Griffin S Richardson G Taylor E Senn S Technology Assessment Report for the HTA Programme: Methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder. Final version London: NICE 2004
15. Arnold LE Treatment alternatives for attention-deficit/hyperactivity disorder Attention Deficit hyperactivity Disorder: State of the Science; Best Practices Kingston, NJ: Civic Research Institute Jensen PJ, Cooper J 2002
16. Centre for Reviews and Dissemination (CRD) CRD Report Number 4. Undertaking systematic reviews of research on effectiveness: CRD's guidance for those carrying out or commissioning reviews York; NHS Centre for Reviews and Dissemination 2 2001
17. Annemans L Ingham M Estimating cost-effectiveness of Concerta OROS in attention-deficit/hyperactivity disorder (ADHD) - Adapting the Canadian Coordinating Office for Health Technology Assessment's (CCOHTA) economic model of methylphenidate immediate release versus behavioural interventions from a parent's perspective Value in Health 2000, 5:6-517
18. Schlander M Cost-effectiveness of methylphenidate OROS for attention-deficit/hyperactivity disorder (ADHD): An evaluation from the perspective of the UK National Health Service (NHS) Value in Health 2004, 7:236
19. Jensen PS Garcia JA Glied S Foster EM Schlander M the MTA Cooperative Group Cost-effectiveness of attention-deficit/hyperactivity disorder (ADHD) treatments: Estimates based upon the MTA study 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) Book of Abstracts. Darmstadt: Steinkopff-Verlag 2004, 219
20. Jensen PS Garcia JA Glied S Crowe M Foster M Schlander M Hinshaw S Vitiello B Arnold LE Elliott G Hechtman L Newcorn JH Pelham WE Swanson J Wells K Cost-effectiveness of ADHD treatments: Findings from the multimodal treatment study of children with ADHD American Journal of Psychiatry 2005, 162(9):1628-1636 10.1176/appi.ajp.162.9.1628 16135621
21. Michelson D Faries D Wernicke J Kelsey D Kendrick K Sallee FR Spencer T Atomoxetine ADHD Study Group Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose response study Pediatrics 2001, 108:1-9 10.1542/peds.108.5.e83 11433046
22. Newcorn JH Owens JA Jasinski DR Results from recently completed comparator studies with atomoxetine and methylphenidate 51st Annual Meeting of the American Academy of Child & Adolescent Psychiatry (AACAP) Washington, DC: Symposium 20 October 21, 2004
23. American Psychiatric Association (APA) Handbook of Psychiatric Measures Washington, DC: APA 2000
24. Collett BR Ohan JL Myers KM Ten-year review of rating scales. V. Scales assessing attention-deficit/hyperactivity disorder Journal of the American Academy for Child and Adolescent Psychiatry 2003, 42:1015-1037 10.1097/01.CHI.0000070245.24125.B6
25. MTA Cooperative Group A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder Archives of General Psychiatry 1999, 56:1073-1086 10.1001/archpsyc.56.12.1073 10591283
26. MTA Cooperative Group Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: The multimodal treatment study of children with attention-deficit/hyperactivity disorder Archives of General Psychiatry 1999, 56:1088-1096 10.1001/ archpsyc.56.12.1088 10591284
27. Arnold LE Sex differences in ADHD: Conference summary Journal of Abnormal Child Psychology 1996, 24:555-569 10.1007/BF01670100 8956084
28. Sonuga-Barke EJS Coghill D Markowitz JS Swanson JM Vandenberghe M Hatch SJ Sex differences in the response of children with ADHD to once-daily formulations of methylphenidate Journal of the American Academy of Child and Adolescent Psychiatry 2007, 46:701-710 10.1097/chi.0b013e31804659f1
29. Faraone SV Sergeant J Gillberg C Biederman J The worldwide prevalence of ADHD: Is it an American condition? World Psychiatry 2003, 2:104-113 1525089 16946911
30. Sharp WS Alter JM Marsh WL Ritchie GF Hamburger SD Castellanos FX ADHD in girls: Clinical comparability of a research sample Journal of the American Academy of Child & Adolescent Psychiatry 1999, 38:40-47 10.1097/00004583-199901000-00018
31. Newcorn J Kratochvil CJ Allen AJ Milton DR Moore RJ Michelson M Atomoxetine and OROS methylphenidate for the treatment of ADHD: Acute results and methodological issues Poster presentation at 45th Annual Meeting of the New Clinical Drug Evaluation Unit (NCDEU) of the National Institute of Mental Health (NIMH) Book of Abstracts Boca Raton FL June 6-9 2005
32. Kemner JE Starr HL Brown DL Ciccone PE Lynch JM Greater symptom improvement and response rates with OROS MPH vs atomoxetine in children with ADHD XXIVth Congress of the Collegium Internationale Neuro-Psychopharmacologicum Paris, France June 20-24, 2004
33. Kemner JE Starr HL Ciccone PE Hooper-Wood CG Crockett RS Outcomes of OROS methylphenidate compared with atomoxetine in children with ADHD: A multicenter, randomized prospective study Advances in Therapy 2005, 22:498-512 16418159
34. Steinhoff K Wigal T Swanson J Single daily dose ADHD medication effect size evaluation 50th Annual Meeting of the American Academy for Child and Adolescent Psychiatry Miami FL October 22-27, 2003
35. Faraone SV Understanding the effect size of ADHD medications: implications for clinical care Medscape 2003, 8:1-7
36. Faraone SV Spencer T Aleardi M Comparing the efficacy of medications used for ADHD using meta-analysis MedGenMed San Francisco, CA 2006, 8: 4 May 17-2 2003 1868385 17415287
37. Faraone SV Biederman J Spencer TJ Aleardi M Comparing the efficacy of medications for ADHD using meta-analysis Medscape General Medicine 2006, 8:4 1868385 17415287
38. Guy W ECDEU Assessment Manual for Psychopharmacology - Revised (DHEW Publ No ADM 76-338) Rockville, MD: Department of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration 1976, 218-222
39. Schachar R Jadad AR Gauld M Boyle M Booker L Snider A Kim M Cunningham C Attention-deficit hyperactivity disorder: Critical appraisal of extended treatment studies Can J Psychiatry 2002, 47:337-348 12025432
40. Klein RG Abikoff HG Hechtman L Weiss G Design and rationale of controlled study of long-term methylphenidate and multimodal psychosocial treatment in children with ADHD Journal of the American Academy of Child and Adolescent Psychiatry 2004, 43:792-801 10.1097/ 01.chi.0000128798.91601.fe
41. Abikoff HG Hechtman L Klein RG Weiss G Fleiss K Etcovitch J Cousins L Greenfield B Martin D Pollack S Symptomatic improvement in children with ADHD treated with long-term methylphenidate and multimodal psychosocial treatment Journal of the American Academy of Child and Adolescent Psychiatry 2004, 43:802-811 10.1097/01.chi.0000128791.10014.ac
42. MTA Cooperative Group National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder Pediatrics 2004, 113(4):754-761 10.1542/peds.113.4.754 15060224
43. Petitti DB Meta-Analysis, Decision Analysis, and Cost-Effectiveness Analysis. Methods for Quantitative synthesis in Medicine New York, Oxford. Oxford University Press 2 2000
44. Schwartz D Lellouch J Explanatory and pragmatic attitudes in therapeutic trials Journal of Chronic Diseases 1967, 20:637-648 10.1016/ 0021-9681(67)90041-0 4860352
45. Weinstein MC O'Brien B Hornberger J Jackson J Johannesson M McCabe C Luce BR Principles of good practice for decision analytic modeling in health-care evaluation: Report of the ISPOR Task Force on good research practices - Modeling studies Value in Health 2003, 6:9-17 10.1046/ j.1524-4733.2003.00234.x 12535234
46. Ramsey S Willke R Briggs A Brown R Buxton M Chawla A Cook J Glick H Liljas B Petitti D Reed S Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA task force report Value in Health 2005, 8:521-533 10.1111/j.1524-4733.2005.00045.x 16176491
47. Claxton A Cramer J Pierce C A systematic review of the associations between dose regimens and medication compliance Clinical Therapeutics 2001, 23:1296-1310 10.1016/S0149-2918(01)80109-0 11558866
48. Hack S Chow B Pediatric psychotropic medication compliance: A literature review and research-based suggestions for improving treatment compliance Journal of Child and Adolescent Psychopharmacology 2001, 11:59-67 10.1089/104454601750143465
49. Swanson J Compliance with stimulants for attention-deficit/hyperactivity disorder. Issues and approaches for improvement CNS Drugs 2003, 17:117-131 10.2165/00023210-200317020-00004 12521359
50. Swanson JM Kinsbourne M Roberts W Zucker K A time-response analysis of the effect of stimulant medication on the learning ability of children referred for hyperactivity Pediatrics 1978, 61:21-29 400817
51. Greenhill LL Pharmacologic treatment of attention deficit hyperactivity disorder Psychiatric Clinics of North America 1992, 15:1-27 1347936
52. Meredith PA Achieving and assessing therapeutic coverage Drug Regimen Compliance: Issues in Clinical Trials and Patient Management Chichester: John Wiley & Sons Métry J-M, Meyer UA 1999, 41-60
53. Peck C Non-compliance and clinical trials: Regulatory perspectives Drug regimen compliance. Issues in clinical trials and patient management Chichester: Wiley Métry J-M, Meyer UA 1999, 97-102
54. American Academy of Child and Adolescent Psychiatry (AACAP) Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults J Am Acad Child Adolesc Psychiatry 2002, 41(2 Suppl):26S-49S 11833633
55. Greenhill LL Perel JM Rudolf G Feldman B Curran S Puig-Antich J Gardner R Correlations between motor persistence and plasma levels of methylphenidate-treated boys with ADHD International Journal of Neuropsychopharmacology 2001, 4:207-215 10.1017/S1461145701002413 11466170
56. Lage M Hwang P Effect of methylphenidate formulation for attention deficit hyperactivity disorder on patterns and outcomes of treatment Journal of Child and Adolescent Psychopharmacology 2004, 14:575-581 10.1089/cap.2004.14.575
57. Marcus SC Wan GJ Kemner JE Olfson M Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder Archives of Pediatrics & Adolescent Medicine 2005, 159:572-578 10.1001/ archpedi.159.6.572 15939858
58. Sanchez RJ Crismon ML Barner JC Bettinger T Wilson JP Assessment of adherence measures with different stimulants among children and adolescents Pharmacotherapy 2005, 25:909-917 10.1592/phco.2005.25.7.909 16006269
59. Kemner JE Lage MJ Effect of methylphenidate formulation on treatment patterns and use of emergency room services American Journal of Health System Pharmacy 2006, 63:317-322 10.2146/ajhp050129 16452517
60. Kemner JE Lage MJ Impact of methylphenidate formulation on treatment patterns and hospitalizations: A retrospective analysis Annals of General Psychiatry 2006, 5:1-8 1360074 16417645 10.1186/1744-859X-5-5
61. Revicki DA Frank L Pharmacoeconomic evaluations in the real world: effectiveness versus efficacy studies Pharmacoeconomics 1999, 15:423-434 10.2165/00019053-199915050-00001 10537960
62. Hughes DA Bagust A Haycox A Walley T Accounting for noncompliance in pharmacoeconomic evaluations Pharmacoeconomics 2001, 19:1185-1197 10.2165/00019053-200119120-00001 11772154
63. March JS Silva SG Compton S Shapiro S Califf R Krishnan R The case for practical clinical trials in psychiatry American Journal of Psychiatry 2005, 162:836-846 10.1176/appi.ajp.162.5.836 15863782
64. Schlander M Long-acting medications for the hyperkinetic disorders. A note on cost-effectiveness Eur Child Adolesc Psychiatry 16 421-429 published online March 30, 2007 10.1007/s00787-007-0615-2 17401606
65. Steele M Riccardelli R Binder C Effectiveness of OROS-methylphenidate vs. usual care with immediate release methylphenidate in ADHD children American Psychiatric Association (APA) Annual Meeting, New York, NY May 1-6th, 2004
66. Steele M Weiss M Swanson J Wang J Prinzo RS Binder CE A randomized, controlled, effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release-methylphenidate in Attention-Deficit-Hyperactivity-Disorder Canadian Journal of Clinical Pharmacology 2006, 13:e50-e62 16456216
67. Coghill D Spender Q Barton J Hollis C Yuen C Cleemput I Annemans L Measuring quality of life in children with attention-deficit/ hyperactivity disorder in the UK 16th World Congress of the International Association for Child and Adolescent Psychiatry and Allied Professions (IACAPAP) Book of Abstracts. Darmstadt: Steinkopff-Verlag 2004, 327
68. Schlander M Impact of attention-deficit/hyperactivity disorder (ADHD) on prescription drug spending for children and adolescents: Increasing relevance of health economic evidence Child Adolesc Psychiatry Ment Health 2007, 1:13 2216002 18005403 10.1186/1753-2000-1-13